噻托溴铵治疗稳定期中重度慢性阻塞性肺疾病的效果观察  

Efficacy of tiotropium in treatment of moderate and severe stable chronic obstructive pulmonary disease

作　　者：姬峰[1] 韩智国[1] 闫金波 许韫[1] 袁圆[1] 

机构地区：[1]武警山东总队医院,济南250014 [2]武警山东总队卫生处

出　　处：《山东医药》2014年第29期15-17,共3页Shandong Medical Journal

摘　　要：目的评价噻托溴铵治疗稳定期中重度慢性阻塞性肺疾病(COPD)患者的临床效果。方法选择稳定期中重度COPD患者56例,随机分为观察组、对照组各28例。对照组给予福莫特罗/布地奈德吸入治疗,观察组给予噻托溴铵联合布地奈德吸入治疗,疗程均为48周。比较两组治疗前后肺功能变化、急性加重次数、间隔时间、呼吸困难评分、生活质量评分。结果观察组治疗48周后,第1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC及深吸气量较治疗前明显改善(P均<0.05),且各指标均优于对照组治疗后(P均<0.05);两组治疗后急性加重次数、间隔时间、生活质量评分、呼吸困难评分较治疗前明显改善(P均<0.05),且观察组改善更明显(P均<0.05)。结论噻托溴铵治疗中重度稳定期COPD患者临床效果较好,值得在临床上推广应用。Objective To evaluate the clinical efficacy of inhaled tiotropium in treatment of patients with moderate to severe stable chronic obstructive pulmonary disease （COPD）.Methods Fifty-six patients with moderate to severe COPD in stable phase were randomly divided into the observation group and control group , 28 in each group.Patients in the con-trol group were treated with symbicort turbuhaler , and patients in the observation group received tiotropium combined budesonide therapy.Both the courses of treatment were 48 weeks.The pulmonary function test, the number of acute episodes, intervals between attacks , SGRQ and MMRC were observed after drug administration in the two groups .Results The first second forced expiratory volume （FEV1）, forced vital capacity （FVC）, FEV1/FVC% and inspiratory capacity （IC） were significantly improved after being treated with tiotropium for 48 weeks （all P〈0.05）.Compared with the control group, the values of FEV1, FVC, FEV1/FVC%and IC were significantly increased in the observation group （all P〈0.05）.The numbers of acute episodes was less , the intervals between attacks was longer and the life quality scores improved in both the two groups as compared with those before treatment （all P〈0.05）, and the observation group improved much better than the control group .Conclusion Tiotropium could improve pulmonary function , reduce the number of exacerbations and intervals , improve quality of life in patients with stable COPD with high safety , which is worthy of clinical promotion.

关 键 词：肺疾病 慢性阻塞性 噻托溴铵 肺功能 

分 类 号：R563[医药卫生—呼吸系统]